WATERTOWN, Mass., July 11,
2024 /PRNewswire/ -- Dynamic Cell Therapies (DCT)
announces an investment of $1M from
the Myeloma Investment Fund (MIF), the venture philanthropy
subsidiary of the Multiple Myeloma Research Foundation (MMRF), to
accelerate the development of novel CAR-T cell technologies for
patients with multiple myeloma. DCT is developing technology
platforms that will allow CAR-T cells to attack unique and
differentiated tumor targets that will allow for durable responses
to treatment, and DCT's proprietary CAR-T cells have demonstrated
superiority to FDA-approved CAR-T cells in animal models. These
technology platforms will improve the safety and efficacy of CAR-T
cell therapies and have immediate application for patients with
hematological cancers, including multiple myeloma. Supported by
this recent investment, DCT is on track to advance a product into
patients within the next two years.
"Despite current successes in treating patients with CAR-T
cells, many patients with multiple myeloma still relapse after
therapy," said Fred Mermelstein,
Ph.D., Chief Executive Officer of DCT. "The support of the MMRF
& the Myeloma Investment Fund provides key expertise that will
enable us to hasten the development of novel and best-in-class
CAR-T cell therapies for patients with relapsed and refractory
multiple myeloma."
"At the MMRF, we are deeply committed to advancing novel
treatments intended to improve patient outcomes and get
us closer to cures. We are energized by DCT's
cutting-edge cell therapy approach as a potentially
transformative answer to patients with relapsed or refractory
myeloma," said Michael
Andreini, President and CEO of the Multiple Myeloma Research
Foundation (MMRF).
About the Myeloma Investment Fund (MIF)
The Myeloma Investment Fund is a venture philanthropy fund that
invests in promising companies, clinical assets, and technologies
in oncology to drive the development of new therapies for multiple
myeloma. The MIF collaborates closely with portfolio companies to
help them advance multiple myeloma research. This evergreen fund is
supported entirely by philanthropy; all profits will be reinvested
back into research for more effective treatments until there is a
cure for every patient. For more information, visit
www.myelomainvestmentfund.org
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) is the largest
nonprofit in the world solely focused on accelerating a cure for
each and every multiple myeloma patient. We drive the development
and delivery of next-generation therapies, leverage data to
identify optimal and more personalized treatment approaches and
empower myeloma patients and the broader community with information
and resources to extend their lives. Central to our mission is our
commitment to advancing health equity so that all myeloma patients
can benefit from the scientific and clinical advances we pursue.
Since our inception, the MMRF has committed over $600 million for research, opened nearly 100
clinical trials, and helped bring 15+ FDA-approved therapies to
market, which have tripled the life expectancy of myeloma patients.
To learn more, visit www.themmrf.org
For MMRF or MIF media inquiries, please contact: Anna Otis, Manager, Brand Marketing, otisa@themmrf.org
About Dynamic Cell Therapies, Inc. (DCT)
Dynamic Cell Therapies (DCT) is a pre-clinical stage
biopharmaceutical company engineering CAR-T cells to address unmet
medical needs for patients with cancers and autoimmune diseases.
DCT has licensed technology from the Dana-Farber Cancer Institute,
including redirectable CAR-T cell and private cytokine signaling
technologies. Redirectable CAR-T cells can maximize tumor cell
killing and minimize toxicity. Private cytokine signaling can
enhance memory populations, which increases CAR-T cells'
persistence and durable responses. DCT is developing these
technologies separately and in combination to optimize control of
CAR-T cell identity and activity. To learn more, visit
www.dynamiccelltherapies.com.
For any DCT inquiries, please contact: Alex Rabby, Chief Business Officer,
arabby@dynamiccelltherapies.com
View original
content:https://www.prnewswire.com/news-releases/myeloma-investment-fund-invests-in-dynamic-cell-therapies-to-help-fuel-novel-car-t-cell-technologies-302194090.html
SOURCE Dynamic Cell Therapies, Inc.